Cystic kidney diseases are one of the most common urogenital malformations and are responsible for a substantial morbidity and mortality. Autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant polycystic kidney disease (ADPKD), multicystic dysplastic kidney (MCDK) and juvenile nephronophthisis (JNP) are the most common and most serious cystic kidney diseases. Hypertension is the main risk factor for progression of various nephropathies, including cystic kidney diseases. The prevalence of hypertension varies depending on the method of BP measurement and the type of cystic disease. Ambulatory BP monitoring (ABPM) is a more potent tool for detection of hypertension than the clinic BP. Hypertension is most common in children with ARPKD, the prevalence ranges between 60 - 100% and hypertension accounts for substantial cardiovascular morbidity and mortality in these patients. In children with ADPKD the prevalence of hypertension is 15 - 38% despite normal renal function and is the most important treatable factor for progression of the disease. Hypertension is a relative uncommon finding in children with MCDK (0 - 20%) and is more often caused by contralateral kidney damage than by affected multicystic kidney. Children with JNP are usually normotensive until the late stages of renal insufficiency. The drugs of first choice in children with cystic kidney diseases are ACE-inhibitors. Most children with ARPKD have severe hypertension and require combination therapy with 2 - 4 drugs (beta-blockers, diuretics, calcium channel blockers). Treatment of hypertension is important not only to delay progression of the kidney disease but also to decrease the cardiovascular morbidity and mortality.
Keywords: Hypertension, ambulatory blood pressure monitoring, polycystic kidney disease, multicystic dysplastic kidney, juvenile nephronophthisis, simple renal cyst, children
Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention Editorial [Hot topic: Hypertension and Diabetes (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy ACE Inhibitor-Angiotensin Receptor Blocker Combinations: A Clinicians Perspective
Mini-Reviews in Medicinal Chemistry Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews Simultaneous Bilateral Basal Ganglia Hemorrhage
Current Drug Delivery Blood Pressure and Cognitive Impairment in the Elderly
Current Hypertension Reviews Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction
Current Hypertension Reviews Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study
Current Vascular Pharmacology Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention Myocardial Insulin Resistance and Cardiac Complications of Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases
Current Vascular Pharmacology